Antibody–Cytokine Fusion Proteins for Cancer Immunotherapy: An Update on Recent Developments
Antibody–Cytokine Fusion Proteins for Cancer Immunotherapy: An Update on Recent Developments
复制标题
用于癌症免疫治疗的抗体-细胞因子融合蛋白:最新进展
DOI:
10.1007/s40259-013-0069-7
复制
发表时间:
2014
期刊:
影响因子:
6.8
通讯作者:
Müller D.
中科院分区:
文献类型:
--
作者:
Müller D.
Treatment with cytokines holds great potential for cancer immunotherapy, but is generally restricted by systemic toxicity. Tumor-directed targeting in the form of antibody fusion proteins appears to be an attractive strategy to overcome this problem. In the last twenty years, continuous efforts in developing appropriate molecules have retrieved a variety of antibody fusion proteins that reveal promising therapeutic effects in preclinical studies. Currently, several candidates are in clinical evaluation. Here, recent developments exploring diverse antibody formats, tumor targets and cytokines of different families as well as strategies addressing cytokine modification or presentation are discussed and clinical trials summarized at a glance. Thus, antibody–cytokine fusion proteins are becoming progressively improving immunologic reagents that raise expectations mainly for combinatorial cancer therapies.
登录
查看更多内容
DOI:
--
发表时间:
2010
期刊:
Protein engineering, design & selection : PEDS
影响因子:
--
作者:
R. Sommavilla;N. Pasche;E. Trachsel;L. Giovannoni;C. Roesli;A. Villa;D. Neri;M. Kaspar
通讯作者:
M. Kaspar
影响因子:
4.4
作者:
B. Gerstmayer;U. Altenschmidt;M. Hoffmann;W. Wels
通讯作者:
W. Wels
影响因子:
6.4
作者:
Marie Vincent;A. Bessard;D. Cochonneau;G. Teppaz;V. Solé;M. Maillasson;S. Birklé;L. Garrigue;A. Quéméner;Y. Jacques
通讯作者:
Y. Jacques
DOI:
10.1073/pnas.0600240103
发表时间:
2006-06-13
影响因子:
11.1
作者:
Rubinstein, Mark P.;Kovar, Marek;Sprent, Jonathan
通讯作者:
Sprent, Jonathan
影响因子:
4.4
作者:
Huang, Tzu-Hsuan;Chintalacharuvu, Koteswara R.;Morrison, Sherie L.
通讯作者:
Morrison, Sherie L.